CD274 and non-small cell lung carcinoma: Therefore, a new milestone was reached when results from the PACIFIC trial were first published in 2017, that investigated a human monoclonal antibody against programmed death-ligand 1 (PD-L1) as consolidation therapy after completed definitive P-CRT in unresectable stage III NSCLC.